[{"uniquePatientKey":"QUNfUEQxLTE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"AC_PD1-1","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzE1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_15","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzMzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_33","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzIyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_22","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxBRERFUi0xNTMzMF9DQ1BNXzA3MDA2Mjk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLADDER-15330_CCPM_0700629","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxBRERFUi0xNTMzMF9DQ1BNXzA3MDA2OTE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLADDER-15330_CCPM_0700691","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxBRERFUi0xNTMzMF9DQ1BNXzA3MDA2OTI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLADDER-15330_CCPM_0700692","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxBRERFUi0xNTMzMF9DQ1BNXzA3MDA2OTQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLADDER-15330_CCPM_0700694","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQV9pbW11bm90aGVyYXB5X3Jlc3BvbmRlci1ERkNJXzExLTEwNF8wMTE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA_immunotherapy_responder-DFCI_11-104_011","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-001","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-002","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDM6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-003","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-005","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-006","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-007","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDg6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-008","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMDk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-009","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMTA6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-010","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMTE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-011","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMTI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-012","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMTQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-014","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMTU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-015","studyId":"mixed_allen_2018"},{"uniquePatientKey":"QkxDQS0wMTY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"BLCA-016","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMDE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_01","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMDQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_04","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMDY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_06","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMDc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_07","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMDk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_09","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMTA6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_10","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMTE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_11","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SU1fMTI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"IM_12","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1Xzk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_9","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q0FOU0VRVTAxLTAxMDA0MjU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CANSEQU01-0100425","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1IwMDk1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR0095","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1IwNDg4NTptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR04885","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1IwNjY3MDptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR06670","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1IxNTA5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR1509","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1IyMjY0MDptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR22640","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1IzNjY1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR3665","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1I2MTI2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR6126","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1I2MTYxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR6161","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1I5MzA2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR9306","studyId":"mixed_allen_2018"},{"uniquePatientKey":"Q1I5Njk5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"CR9699","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1Xzg6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_8","studyId":"mixed_allen_2018"},{"uniquePatientKey":"REZDSV9NTV8xOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"DFCI_MM_1","studyId":"mixed_allen_2018"},{"uniquePatientKey":"REZDSV9NTV8yOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"DFCI_MM_2","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzE4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_18","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzI0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_24","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzExOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_11","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzIzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_23","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_2","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMTg2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-186","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjE1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-215","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjM4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-238","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjM5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-239","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjQzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-243","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjU4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-258","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjY2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-266","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjg3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-287","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMjk2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-296","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMzA1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-305","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMzA2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-306","studyId":"mixed_allen_2018"},{"uniquePatientKey":"SE5TQ0MtMzIzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"HNSCC-323","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzE2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_16","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzEyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_12","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzI4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_28","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzI5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_29","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TFNEMDE2NzptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"LSD0167","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TFNEMjA1NzptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"LSD2057","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TFNEMzQ4NDptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"LSD3484","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TFNENDc0NDptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"LSD4744","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TFNENjgxOTptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"LSD6819","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDI2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1026","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDIyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1022","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDM3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1037","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDM4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1038","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDM5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1039","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDI5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1029","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDI3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1027","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDMwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1030","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDI0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1024","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDI4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1028","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDM0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1034","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDI1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1025","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDIxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1021","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDM1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1035","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TFVORy0yNjMwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"LUNG-2630","studyId":"mixed_allen_2018"},{"uniquePatientKey":"REZDSS0xMS0xMDQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"DFCI-11-104","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_5","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzEzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_13","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TUVMLTU4MjE4NjptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"MEL-582186","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TUVMLTU4Nzc2MTptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"MEL-587761","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TUVMLTY1MDM2NjptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"MEL-650366","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TUVMLTY4MjMyMTptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"MEL-682321","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MDI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat02","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MDM6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat03","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MDQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat04","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MDY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat06","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MDc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat07","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MDg6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat08","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTAwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat100","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTAxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat101","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTAzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat103","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTA0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat104","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTA1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat105","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTA2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat106","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat11","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTEwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat110","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTExOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat111","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTEzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat113","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTE1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat115","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTE3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat117","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTE4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat118","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTE5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat119","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat12","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTIxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat121","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTIzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat123","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTI0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat124","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTI2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat126","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTI3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat127","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTI4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat128","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTI5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat129","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTM6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat13","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTMyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat132","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTMzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat133","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTM0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat134","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTM1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat135","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTM4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat138","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTM5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat139","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat14","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTQwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat140","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTQzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat143","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTQ0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat144","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTQ3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat147","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTQ4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat148","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat15","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTUxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat151","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTU3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat157","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTU5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat159","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat16","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTYwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat160","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTYyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat162","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTYzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat163","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTY2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat166","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTY3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat167","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTY4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat168","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat17","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTcwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat170","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTcxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat171","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTc0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat174","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTc1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat175","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MTg6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat18","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MjE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat21","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MjQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat24","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0Mjc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat27","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0MzI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat32","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0Mzk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat39","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NDE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat41","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NDM6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat43","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NDU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat45","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NDY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat46","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NDc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat47","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NDk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat49","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTA6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat50","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat52","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat54","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat55","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat56","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat57","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTg6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat58","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NTk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat59","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NjA6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat60","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NjE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat61","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NjI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat62","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NjQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat64","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NjY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat66","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0Njc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat67","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NzE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat71","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NzM6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat73","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NzQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat74","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0NzY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat76","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0Nzc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat77","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0Nzk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat79","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0ODA6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat80","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0ODE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat81","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0ODI6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat82","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0ODM6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat83","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0ODU6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat85","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0ODY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat86","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0ODc6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat87","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0OTA6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat90","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0OTg6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat98","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UGF0OTk6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"Pat99","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzMyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_32","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlIxODY3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR1867","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlIyMTM3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR2137","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlIzNTQ5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR3549","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI0MDE4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR4018","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI0MDQ1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR4045","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI0MDgzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR4083","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI0NjMxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR4631","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI0ODEwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR4810","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI0OTQ5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR4949","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI4ODE1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR8815","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI5NDQ1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR9445","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI5NDQ5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR9449","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI5NTIxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR9521","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI5NzA1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR9705","studyId":"mixed_allen_2018"},{"uniquePatientKey":"TlI5NzY1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"NR9765","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UFIxMjExNzptaXhlZF9hbGxlbl8yMDE4","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"PR12117","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UFI0MDM1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"PR4035","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UFI0MDQ2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"PR4046","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UFI0MDc3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"PR4077","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UFI0MDkxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"PR4091","studyId":"mixed_allen_2018"},{"uniquePatientKey":"UFI0MDkyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"PR4092","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzI1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_25","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzIwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_20","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzY6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_6","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzI3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_27","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_1","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0FSQy1QRDE6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SARC-PD1","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzE5Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_19","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzEwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_10","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzIxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_21","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0QwMzQ2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD0346","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0QxNDk0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD1494","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0QyMDUxOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD2051","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0QyMDU2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD2056","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0Q1MDM4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD5038","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0Q1MTE4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD5118","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0Q1OTM0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD5934","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0Q2MzM2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD6336","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0Q2NDk0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD6494","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U0Q3MzU3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SD7357","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzE3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_17","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDAyOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1002","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDAzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1003","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDA0Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1004","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDA1Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1005","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDA2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1006","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDEwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1010","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDExOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1011","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDEzOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1013","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDE2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1016","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDE3Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1017","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDE4Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1018","studyId":"mixed_allen_2018"},{"uniquePatientKey":"U1UyQy0xMDIwOm1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"SU2C-1020","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzI2Om1peGVkX2FsbGVuXzIwMTg","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_26","studyId":"mixed_allen_2018"},{"uniquePatientKey":"bHVhZF9tc2tjY18yMDE1XzQ6bWl4ZWRfYWxsZW5fMjAxOA","cancerStudy":{"name":"MSS Mixed Solid Tumors (Broad/Dana-Farber, Nat Genet 2018)","description":"Whole exome sequencing of tumor/normal pairs and corresponding clinical outcomes from patients treated with immune checkpoint inhibitors across multiple cancer types including melanoma, non-small cell lung cancer, head and neck cancer, and bladder cancer.","publicStudy":true,"pmid":"30150660","citation":"Miao et al. Nat Genet 2018","groups":"","status":0,"importDate":"2026-01-08 15:10:03","readPermission":true,"studyId":"mixed_allen_2018","cancerTypeId":"mixed","referenceGenome":"hg19"},"patientId":"luad_mskcc_2015_4","studyId":"mixed_allen_2018"}]